Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814164 · ClinicalTrials.gov registry record · Phase 2
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00814164 is a Phase 2 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 21 participants.
The verdict
NCT00814164, a Phase 2 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as clofarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving clofarabine together with daunorubicin may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving clofarabine together with daunorubicin works in treating older patients with newly diagnosed acute myeloid leukemia.
Interventions
- GENETIC protein expression analysis
- DRUG clofarabine
- GENETIC cytogenetic analysis
- DRUG daunorubicin hydrochloride
- OTHER immunologic technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814164
The ClinicalTrials.gov registry entry for NCT00814164 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00814164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814164 about?
NCT00814164 is a clinical study titled "Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as clofarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving clofarabine together with daunorubicin may kill more cancer cells. PURPOSE: This phase II tri...
What is the current status of trial NCT00814164?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2008-12. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00814164?
The interventions under investigation include: protein expression analysis (GENETIC), clofarabine (DRUG), cytogenetic analysis (GENETIC), daunorubicin hydrochloride (DRUG), immunologic technique (OTHER).
Who is sponsoring clinical trial NCT00814164?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.